A Rare Tumoral Combination, Renal Cell Carcinoma, Breast Carcinoma and Non- Hodgkin Lymphoma and Review of the Literature
*Didem Karacetin Department Of Radiation Oncology, Istanbul Research And Training Hosp?tal, Turkey
*Corresponding Author: Didem Karacetin
Department Of Radiation Oncology, Istanbul Research And Training Hosp?tal, Turkey Email:email@example.com
Published on: 2017-10-18
Multiple consecutive cancers involving different organs in a female individual are presented. Here in, we present a rare case of primary left renal cell carcinoma (RCC), in which two different malignancies of left cervical lymph node and left breast were occurred consecutively. We present the case of a 84-year-old female with three primary malignant neoplasms detected synchronously. She was admitted to our clinic with left neck upper mass.The result of the left cervical lymph node biopsy revealed diffuse B large cell lymphoma, the result of the left breast biopsy revealed well differantiated invasive ductal carcinoma and the result of the kidney’s noduler biopsy was clear cell carcinoma respectively. Rituximab chemotherapy was started as the lymphoma treatment because of the patients age and low performance status. Pathological assessment of newly detected lesions in multiple primary cancer cases is important for the treatment approach.
Renal Cell Carcinoma; Breast Carcinoma; Non- Hodgkin Lymphoma
Multiple primary cancers are defined as occurrence of two or more malignancies, synchronous or metachronous, in different organs without any relation to each other. Cancer survivors are a growing group owing to improvements in scanning and treatment. In this group the most serious event is the diagnosis of a new second cancer. Also older people population increases. Because of these two reasons multiple primary cancers are likely to increase. Cancer patients have a 20% higher risk of new primary cancer, in the same organ or in another organ, compared with the general population. Also, second cancers have become a leading cause of death among long-term cancer survivors.